Cyclacel completes enrollment in Cohort 8 of Phase 2 study of fadraciclib

Cyclacel Pharmaceuticals announced that enrollment of 12 patients has been completed as per protocol in Cohort 8 of its Phase 2 stage, proof of concept 065-101 study of fadraciclib, a CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma. Enrollment of Cohort 5 in patients with T-Cell Lymphoma is continuing. “We are pleased to report that the Cyclacel team has achieved another important milestone by completing enrollment of the patient cohort with CDKN2A/B abnormalities,” said Spiro Rombotis, President and Chief Executive Officer. “The rapid pace of enrollment of approximately six months, since opening the cohort in mid-May, underscores the great unmet medical need of cancer patients with CDKN2A/B abnormalities. Updated safety and efficacy data from the 065-101 study of fadra has been accepted for presentation during the upcoming 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics”